Skip to content

A randomized double blind placebo parallel controlled study on the effect of decoction of Caulis Lonicerae on the plaque fiber cap thickness in patients with carotid atherosclerosis

A randomized double blind placebo parallel controlled study on the effect of decoction of Caulis Lonicerae on the plaque fiber cap thickness in patients with carotid atherosclerosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039786
Enrollment
Unknown
Registered
2020-11-09
Start date
2020-11-16
Completion date
Unknown
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid atherosclerosis

Interventions

Sponsors

Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The patients with carotid atherosclerotic plaques were diagnosed by color Doppler ultrasound; 2. hsCRP >= 2 mg/L; 3. Patients between 40 and 80 years old, regardless of gender; 4. Patients who can take medicine for a long time; 5. Patients who have informed consent and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1.Acute or subacute hemorrhage in plaque; 2.Plaque is calcified and fibrotic; 3.Can not do MRI(such as carrying a pacemakerdenturecardiac stent); 4.Patients with active ulcers and bleeding tendency who take anticoagulants (such as warfarin) for a long time; 5.Patients are using dual antiplatelet drugs; 6.Patients with serious arrhythmia, atrial fibrillation and heart failure; 7.Patients with severe liver, kidney, hematopoietic system, endocrine system, respiratory system, hypertension, infectious and non infectious inflammation, immune related and other primary diseases, whose liver function is more than 1.5 times higher than the upper limit of the normal value, and whose Cr is higher than the normal value; 8.Any other life-threatening or serious disease that cannot be treated for 12 months and thus affects the evaluation results; 9.Pregnant or lactating women, women with a recent pregnancy plan; 10.Patients with allergic constitution; 11.Other diseases or psychosis that may limit efficacy evaluation or patient follow-up in the opinion of researchers; 12.Patients who have participated in clinical trials of other drugs in the past 4 weeks.

Design outcomes

Primary

MeasureTime frame
Minimum fiber cap thickness;

Secondary

MeasureTime frame
Volume of Lipid-Rich Necrotic Core;Volume percentage of Lipid-Rich Necrotic Core;Carotid Atherosclerosis Score;Volume of Fiber cap;Volume percentage of Fiber cap;Volume of bleeding in plaque;Volume percentage of bleeding in plaque;Volume of plaque calcification;Volume percentage of plaque calcification;Vascular stenosis rate;Average value of vascular wall thickness;Maximum vascular wall thickness;Volume of vascular wall;Total vessel wall load (volume of vascular wall/total volume of blood vessels);Weight;Blood lipid;Blood glucose;Blood pressure;High-sensitivityC-reactive protein;

Countries

China

Contacts

Public ContactWu Shengxian

Dongzhimen Hospital of Beijing University of traditional Chinese Medicine

wushx@sina.com+86 13501382919

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026